Status:
ACTIVE_NOT_RECRUITING
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Stomach Cancer
Gastro Esophageal Junction Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherap...
Detailed Description
In this single-centre, open-label, monocenter study, the investigators will enroll 20 patients with resectable cancer of the stomach of GEJunction. All patients will be treated with 1 cycle of atezol...
Eligibility Criteria
Inclusion
- signed informed consent
- patients age 18 and older
- primary resectable, histologically confirmed gastric or GEJ adenocarcinoma
Exclusion
- no signs of distant metastases
- no active or history of autoimmune disease or immune deficiency
- no significant cardiovascular disease
- no major surgical procedure within 4 weeks prior to initiation of study treatment
- no current treatment with anti-viral therapy or HBV
- no pregnancy or breastfeeding
- no history of malignancy within 3 years prior to screening
Key Trial Info
Start Date :
March 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03448835
Start Date
March 7 2018
End Date
October 31 2026
Last Update
June 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Marieke van de Belt
Amsterdam, Netherlands, 1066CX
2
Catharina ziekenhuis
Eindhoven, Netherlands